These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

162 related items for PubMed ID: 14999613

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Effect of zidovudine resistance mutations on virologic response to treatment with zidovudine-lamivudine-ritonavir: genotypic analysis of human immunodeficiency virus type 1 isolates from AIDS clinical trials group protocol 315.ACTG Protocol 315 Team.
    Kuritzkes DR, Sevin A, Young B, Bakhtiari M, Wu H, St Clair M, Connick E, Landay A, Spritzler J, Kessler H, Lederman MM.
    J Infect Dis; 2000 Feb; 181(2):491-7. PubMed ID: 10669331
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. HIV-1 drug resistance in subjects with advanced HIV-1 infection in whom antiretroviral combination therapy is failing: a substudy of AIDS Clinical Trials Group Protocol 388.
    Demeter LM, Ribaudo HJ, Erice A, Eshleman SH, Hammer SM, Hellmann NS, Fischl MA, AIDS Clinical Trials Group Protocol 388.
    Clin Infect Dis; 2004 Aug 15; 39(4):552-8. PubMed ID: 15356820
    [Abstract] [Full Text] [Related]

  • 6. Long-term virologic and immunologic responses in human immunodeficiency virus type 1-infected children treated with indinavir, zidovudine, and lamivudine.
    Jankelevich S, Mueller BU, Mackall CL, Smith S, Zwerski S, Wood LV, Zeichner SL, Serchuck L, Steinberg SM, Nelson RP, Sleasman JW, Nguyen BY, Pizzo PA, Yarchoan R.
    J Infect Dis; 2001 Apr 01; 183(7):1116-20. PubMed ID: 11237839
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Diminished selection for thymidine-analog mutations associated with the presence of M184V in Ethiopian children infected with HIV subtype C receiving lamivudine-containing therapy.
    Averbuch D, Schapiro JM, Lanier ER, Gradstein S, Gottesman G, Kedem E, Einhorn M, Grisaru-Soen G, Ofir M, Engelhard D, Grossman Z.
    Pediatr Infect Dis J; 2006 Nov 01; 25(11):1049-56. PubMed ID: 17072129
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Transmission of HIV-1 minority-resistant variants and response to first-line antiretroviral therapy.
    Peuchant O, Thiébaut R, Capdepont S, Lavignolle-Aurillac V, Neau D, Morlat P, Dabis F, Fleury H, Masquelier B, ANRS CO3 Aquitaine Cohort.
    AIDS; 2008 Jul 31; 22(12):1417-23. PubMed ID: 18614864
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Mechanisms of virologic failure in previously untreated HIV-infected patients from a trial of induction-maintenance therapy. Trilège (Agence Nationale de Recherches sur le SIDA 072) Study Team).
    Descamps D, Flandre P, Calvez V, Peytavin G, Meiffredy V, Collin G, Delaugerre C, Robert-Delmas S, Bazin B, Aboulker JP, Pialoux G, Raffi F, Brun-Vézinet F.
    JAMA; 2000 Jan 12; 283(2):205-11. PubMed ID: 10634336
    [Abstract] [Full Text] [Related]

  • 15. Virological response in multidrug-experienced HIV-1-infected subjects failing highly active combination regimens after shifting from lamivudine to didanosine.
    Rusconi S, La Seta Catamancio S, Citterio P, Bulgheroni E, Kurtagic S, Galazzi M, Croce F, Moroni M, Galli M.
    Antivir Ther; 2001 Mar 12; 6(1):41-6. PubMed ID: 11417760
    [Abstract] [Full Text] [Related]

  • 16. Genotypic resistance analyses in nucleoside-pretreated patients failing an indinavir containing regimen: results from a randomized comparative trial: (Novavir ANRS 073).
    Descamps D, Joly V, Flandre P, Peytavin G, Meiffrédy V, Delarue S, Lastère S, Aboulker JP, Yeni P, Brun-Vézinet F.
    J Clin Virol; 2005 Jun 12; 33(2):99-103. PubMed ID: 15911424
    [Abstract] [Full Text] [Related]

  • 17. Selection of zidovudine resistance mutations and escape of human immunodeficiency virus type 1 from antiretroviral pressure in stavudine-treated pediatric patients.
    Maxeiner HG, Keulen W, Schuurman R, Bijen M, de Graaf L, van Wijk A, Back N, Kline MW, Boucher CA, Nijhuis M.
    J Infect Dis; 2002 Apr 15; 185(8):1070-6. PubMed ID: 11930317
    [Abstract] [Full Text] [Related]

  • 18. Efficacy and safety of indinavir/ritonavir 400/100 mg twice daily plus two nucleoside analogues in treatment-naive HIV-1-infected patients with CD4+ T-cell counts <200 cells/mm3: 96-week outcomes.
    Mootsikapun P, Chetchotisakd P, Anunnatsiri S, Boonyaprawit P.
    Antivir Ther; 2005 Apr 15; 10(8):911-6. PubMed ID: 16430196
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Impact of indinavir on the quality of life in patients with advanced HIV infection treated with zidovudine and lamivudine.
    Coplan PM, Cook JR, Carides GW, Heyse JF, Wu AW, Hammer SM, Nguyen BY, Meibohm AR, DiNubile MJ, AIDS Clinical Trials Group 320 Study Team.
    Clin Infect Dis; 2004 Aug 01; 39(3):426-33. PubMed ID: 15307012
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.